Speciality: Hematology
Description:
A warm welcome to all the medical professionals for The Conclusion of our "An Eagle's View" session on Iron Deficiency Anemia. We have taken an evidence-based approach to understanding IDA, and this concluding segment will synthesize our findings into actionable clinical takeaways. The key conclusion is that while oral iron remains a valid first-line option, a more patient-centric and proactive approach, heavily informed by recent data, is essential to close the care gap and improve patient outcomes.
The evidence points to a paradigm shift, where intravenous iron is no longer a last resort but a powerful and safe tool for rapid and effective iron repletion. Recent data support its use in specific patient populations, including those with severe anemia, a need for rapid correction, intolerance to oral iron, or co-morbidities like chronic heart failure and inflammatory bowel disease. This is crucial as a significant portion of patients do not achieve adequate iron repletion with oral supplements alone, leading to persistent symptoms and a reduced quality of life.
Therefore, the ultimate conclusion of this session is a call to action: to critically evaluate each patient's needs and consider the most effective and efficient treatment path from the outset. By integrating a deep understanding of the pros and cons of both oral and intravenous iron, medical professionals can empower themselves to make informed decisions that will directly and positively impact patient well-being. Continue to follow Hidoc for more such indispensable sessions that keep you at the forefront of medical advancements.
See More Webinars @ Hidoc Webinars
1.
In a study, immune detection of oral cancers is linked to obesity.
2.
FDA approves rivanetin as the first-line treatment for lung cancer.
3.
Extended Maintenance with Imatinib Enhances Disease-Free Survival in High-Risk GIST.
4.
Regular physical activity before cancer diagnosis may lower progression and death risks
5.
Alternative Medicine for Breast Cancer: Study Raises Concern
1.
What is Red Cell Distribution Width and Why Should You Care?
2.
Mast Cell-Tumor Cell Interactions in OSCC: Genetic and microRNA Insights
3.
Targeted Therapy: Latest Advances, Learning Tools, Trials & Treatment Options Explained
4.
Hemophilia B and Gene Therapy: A New Chapter with Etranacogene Dezaparvovec
5.
AI-Powered Rehabilitation: A Game Changer for Hemophilia Management
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Efficient Management of First line ALK-rearranged NSCLC - Part IV
2.
Summary of The Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2
3.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VII
4.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part I
5.
Navigating the Complexities of Ph Negative ALL - Part X
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation